--- title: "Kalaris Therapeutics (KLRS) news: merger" url: "https://aibio.space/companies/kalaris-therapeutics/" publisher: "aibio.space (Biotech Investor Relations News)" summary: "KLRS merger news: AlloVir (now Kalaris Therapeutics) completes Kalaris merger; shares to trade as KLRS on March 19. Kalaris Therapeutics, Inc." --- KLRS Kalaris Therapeutics, Inc. NASDAQ · United States # Kalaris Therapeutics (KLRS) news KLRS merger news Mergers · 2025-03-18 ## [AlloVir (now Kalaris Therapeutics) completes Kalaris merger; shares to trade as KLRS on March 19](https://aibio.space/news/allovir-now-kalaris-therapeutics-completes-kalaris-merger-shares-trade/) The combined company expects about $100 million in cash at closing to fund operations into the fourth quarter of 2026, while its lead drug candidate, TH103, is still in an open-label Phase 1 trial. Former Kalaris holders own about 74.47% on a fully diluted basis. ## Latest Kalaris Therapeutics news 1. 2025-03-18 Mergers [Kalaris Therapeutics closes merger with AlloVir; stock trades as KLRS from March 19, 2025](https://aibio.space/news/kalaris-therapeutics-closes-merger-allovir-stock-trades-klrs-march-19/) Pre-merger Kalaris holders own about 74.47% of the combined company. Cash of about $100 million is expected to last into the fourth quarter of 2026. 2. 2025-03-12 Mergers [AlloVir (now Kalaris Therapeutics) stockholders approve Kalaris merger and change of control](https://aibio.space/news/allovir-now-kalaris-therapeutics-stockholders-approve-kalaris-merger/) At a March 12, 2025 special meeting, AlloVir holders approved the share issuance and change of control under Nasdaq rules, and a stock plan increase. The merger is expected to close as soon as practicable. 3. 2025-03-12 Mergers [AlloVir (now Kalaris Therapeutics) stockholders approve merger with Kalaris](https://aibio.space/news/allovir-now-kalaris-therapeutics-stockholders-approve-merger-kalaris/) AlloVir holders backed all proposals at a special meeting on March 12, 2025. The combined company is expected to be renamed Kalaris Therapeutics and trade on Nasdaq as KLRS. ## Kalaris Therapeutics at a glance - **Ticker**: KLRS - **Listing**: NASDAQ - **Country**: United States - **Cash, Jun 30, 2026**: $93.5 million ### Related companies - [Humacyte](https://aibio.space/companies/humacyte/) NASDAQ: HUMA - [Statera Biopharma](https://aibio.space/companies/statera-biopharma/) OTC: STAB - [Microbot Medical](https://aibio.space/companies/microbot-medical/) NASDAQ: MBOT - [Zentalis Pharmaceuticals](https://aibio.space/companies/zentalis-pharmaceuticals/) NASDAQ: ZNTL - [GB Sciences](https://aibio.space/companies/gb-sciences/) OTC: GBLX - [FibroBiologics](https://aibio.space/companies/fibrobiologics/) NASDAQ: FBLG - [ANI Pharmaceuticals](https://aibio.space/companies/ani-pharmaceuticals/) NASDAQ: ANIP - [Krystal Biotech](https://aibio.space/companies/krystal-biotech/) NASDAQ: KRYS ### Also on NASDAQ - [Lisata Therapeutics](https://aibio.space/companies/lisata-therapeutics/) LSTA - [Ultragenyx Pharmaceutical](https://aibio.space/companies/ultragenyx-pharmaceutical/) RARE - [Immunocore Holdings](https://aibio.space/companies/immunocore/) IMCR - [Anixa Biosciences](https://aibio.space/companies/anixa-biosciences/) ANIX - [Cocrystal Pharma](https://aibio.space/companies/cocrystal-pharma/) COCP - [TRINITY BIOTECH](https://aibio.space/companies/trinity-biotech/) TRIB ## Kalaris Therapeutics annual financials | Line | FY2025 | FY2024 | |---|---|---| | Research and development | [$30.8 million](https://www.sec.gov/Archives/edgar/data/1754068/000119312526110659/) | [$45.0 million](https://www.sec.gov/Archives/edgar/data/1754068/000119312526110659/) | | Net income (loss) | [-$43.4 million](https://www.sec.gov/Archives/edgar/data/1754068/000119312526110659/) | [-$69.2 million](https://www.sec.gov/Archives/edgar/data/1754068/000119312526110659/) | | Cash from operations | [-$38.4 million](https://www.sec.gov/Archives/edgar/data/1754068/000119312526110659/) | [-$20.7 million](https://www.sec.gov/Archives/edgar/data/1754068/000119312526110659/) | | Cash and equivalents | [$98.1 million](https://www.sec.gov/Archives/edgar/data/1754068/000119312526344532/) | [$1.6 million](https://www.sec.gov/Archives/edgar/data/1754068/000119312526110659/) | | Short-term investments | [$19.9 million](https://www.sec.gov/Archives/edgar/data/1754068/000119312526344532/) | [$0](https://www.sec.gov/Archives/edgar/data/1754068/000119312526110659/) | Latest balance sheet, Jun 30, 2026 (10-Q): cash and equivalents $43.2 million, plus short-term investments of $50.4 million, $93.5 million in all. Figures as reported to the SEC in XBRL; each one links to its filing. Not adjusted, not investment advice. ## Questions about Kalaris Therapeutics Is Kalaris Therapeutics involved in a merger or acquisition? Our latest story on this, dated Mar 18, 2025: "AlloVir (now Kalaris Therapeutics) completes Kalaris merger; shares to trade as KLRS on March 19". The story links the filing or release it is based on. [Read the story](https://aibio.space/news/allovir-now-kalaris-therapeutics-completes-kalaris-merger-shares-trade/). What is the ticker symbol of Kalaris Therapeutics? Kalaris Therapeutics, Inc. trades under the ticker KLRS on NASDAQ. Where is Kalaris Therapeutics listed? Kalaris Therapeutics, Inc. is listed on NASDAQ. What is the SEC CIK of Kalaris Therapeutics? The SEC Central Index Key (CIK) for Kalaris Therapeutics, Inc. is 1754068. Its filings are on SEC EDGAR. How many shares does Kalaris Therapeutics have outstanding? 23,804,981 shares as of 2026-08-04, per the cover page of its 10-Q filed 2026-08-11. Which country or territory is Kalaris Therapeutics listed under? Our directory records Kalaris Therapeutics, Inc. under United States. What does Kalaris Therapeutics do? Our directory classifies Kalaris Therapeutics, Inc. as: Biotechnology. This is a directory classification, not a description of the pipeline. What is the ISIN of Kalaris Therapeutics? The ISIN recorded for Kalaris Therapeutics, Inc. is US4829291065. Does aibio.space cover Kalaris Therapeutics? aibio.space lists Kalaris Therapeutics, Inc. among 2,820 public biotech companies and publishes its news here as stories appear. Where is Kalaris Therapeutics incorporated? SEC records list its state or country of incorporation as DE. Is Kalaris Therapeutics profitable? Kalaris Therapeutics, Inc. reported a net loss of $43.4 million for the fiscal year ended Dec 31, 2025, and used $38.4 million of cash in operations, per its annual report to the SEC. How much does Kalaris Therapeutics spend on research and development? $30.8 million in the fiscal year ended Dec 31, 2025, per its annual report. How much cash does Kalaris Therapeutics have? $93.5 million in cash and short-term investments at Jun 30, 2026, per its 10-Q. What is the latest Kalaris Therapeutics (KLRS) stock news? Our latest story on Kalaris Therapeutics, dated Mar 18, 2025: "AlloVir (now Kalaris Therapeutics) completes Kalaris merger; shares to trade as KLRS on March 19". The combined company expects about $100 million in cash at closing to fund operations into the fourth quarter of 2026, while its lead drug candidate, TH103, is still in an open-label Phase 1 trial. Former Kalaris holders own about 74.47% on a fully diluted basis. [Source](https://aibio.space/news/allovir-now-kalaris-therapeutics-completes-kalaris-merger-shares-trade/). How long will Kalaris Therapeutics's cash last? From our story of Mar 18, 2025: The combined company expects about $100 million in cash at closing to fund operations into the fourth quarter of 2026, while its lead drug candidate, TH103, is still in an open-label Phase 1 trial. [Source](https://aibio.space/news/allovir-now-kalaris-therapeutics-completes-kalaris-merger-shares-trade/). ## Investor discussion: Kalaris Therapeutics Members talk about Kalaris Therapeutics (KLRS). Reader posts, not aibio.space reporting, and not investment advice. Rules 1. **Securities violations are strictly forbidden.** No market manipulation, no pump-and-dump, no false or misleading statements, and no inside information. 2. **Say whether you hold the stock.** Every post states long, short or no position. 3. **No paid or sponsored posts.** Do not post for anyone who pays or rewards you. 4. **No buy or sell calls and no price targets.** 5. **No accusations of crime or fraud against named people** unless you link a court filing or a regulator's release that makes them. 6. **No personal details and no spam.** No links at all for your first 7 days as a member. Posts that break the rules may be deleted without notice, and the account restricted or closed. See the [terms](https://aibio.space/terms/#discussion) and the [privacy policy](https://aibio.space/privacy/#discussion). ## Capital-markets timeline Financings, listing notices, splits, legal actions and other investor events at Kalaris Therapeutics, newest first. Each line links the filing it comes from. 1. 2026-04-03 Financings Set up an at-the-market program to sell shares over time. SEC Form S-3. [Source](https://www.sec.gov/Archives/edgar/data/1754068/000119312526142151/d143090ds3.htm) 2. 2026-03-09 Financings Reported a financing. SEC Form 8-K (Items 7.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1754068/000119312526097548/d122695dex991.htm) 3. 2025-12-18 Financings Reported a financing. SEC Form 8-K (Items 1.01,3.02,8.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1754068/000119312525323706/d48530dex991.htm) 4. 2025-08-13 Legal Disclosed a shareholder lawsuit, subpoena or other legal matter. SEC Form 10-Q. [Source](https://www.sec.gov/Archives/edgar/data/1754068/000095017025107979/klrs-20250630.htm) 5. 2025-03-18 Mergers Reported completing an acquisition or a sale of assets. SEC Form 8-K (Items 2.01,2.02,5.01,5.02,5.03,5.06,7.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1754068/000119312525056725/d925335dex991.htm) 6. 2025-03-12 Mergers Reported a merger or acquisition agreement. SEC Form 8-K (Items 5.02,5.07,8.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1754068/000119312525052940/d347915dex992.htm) 7. 2025-01-15 Listings Reported a reverse stock split. SEC Form 8-K (Items 3.03,5.03,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1754068/000119312525007077/d900097d8k.htm) 8. 2025-01-10 Listings Reported a shareholder vote on a reverse stock split or more authorized shares. SEC Form 8-K (Items 5.07). [Source](https://www.sec.gov/Archives/edgar/data/1754068/000119312525004091/d899696d8k.htm) 9. 2025-01-10 Listings Reported a reverse stock split. SEC Form 8-K (Items 8.01). [Source](https://www.sec.gov/Archives/edgar/data/1754068/000119312525004527/d834173d8k.htm) 10. 2024-12-06 Listings Asked shareholders to approve a reverse stock split. SEC Form DEF 14A. [Source](https://www.sec.gov/Archives/edgar/data/1754068/000119312524271972/d902309ddef14a.htm) 11. 2024-11-26 Listings Asked shareholders to approve a reverse stock split. SEC Form PRE 14A. [Source](https://www.sec.gov/Archives/edgar/data/1754068/000119312524266145/d902309dpre14a.htm) 12. 2024-11-08 Mergers Reported a merger or acquisition agreement. SEC Form 8-K (Items 1.01,7.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1754068/000119312524253747/d870301dex991.htm) ## Stock chart Price chart and quote supplied by TradingView, delayed as the exchange requires. It loads only if you choose to show it. Information only, not investment advice. [Open NASDAQ:KLRS on TradingView](https://www.tradingview.com/symbols/NASDAQ-KLRS/). ## SEC filings and registration - **SEC name**: Kalaris Therapeutics, Inc. - **CIK**: 1754068 - **Industry (SIC)**: Biological Products, (No Diagnostic Substances) (2836) - **US tickers**: KLRS (Nasdaq) - **State or country of incorporation**: DE - **Fiscal year ends**: December 31 - **Filer category**: Non-accelerated filer
Smaller reporting company - **Business address**: 400 CONNELL DRIVE, BERKELEY HEIGHTS, NJ, 07922 - **Phone**: 650-249-2727 - **Shares outstanding**: 23,804,981 as of 2026-08-04 (10-Q filed 2026-08-11) - **Former names**: Allovir, Inc.; ViraCyte, Inc. ### Recent filings (8-K and 6-K are the company's own announcements) - [10-Q](https://www.sec.gov/Archives/edgar/data/1754068/000119312526344532/klrs-20260630.htm) filed 2026-08-11 - [8-K](https://www.sec.gov/Archives/edgar/data/1754068/000119312526343477/d114296d8k.htm) filed 2026-08-11 - [8-K](https://www.sec.gov/Archives/edgar/data/1754068/000119312526308382/d125092d8k.htm) filed 2026-07-20 - [8-K](https://www.sec.gov/Archives/edgar/data/1754068/000119312526306737/d125006d8k.htm) filed 2026-07-17 - [8-K](https://www.sec.gov/Archives/edgar/data/1754068/000119312526296190/d34897d8k.htm) filed 2026-07-06 - [8-K](https://www.sec.gov/Archives/edgar/data/1754068/000119312526257388/d85626d8k.htm) filed 2026-06-04 - [10-Q](https://www.sec.gov/Archives/edgar/data/1754068/000119312526219328/klrs-20260331.htm) filed 2026-05-12 - [8-K](https://www.sec.gov/Archives/edgar/data/1754068/000119312526218240/d24879d8k.htm) filed 2026-05-12 Source: [SEC EDGAR](https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001754068), retrieved October 23, 2026. Shares outstanding is the cover-page figure from the latest periodic report. The SEC does not publish share prices. ## Listing details Kalaris Therapeutics, Inc. is a public biotech or pharmaceutical company listed on NASDAQ under the ticker KLRS, recorded under United States. The directory classifies it as Biotechnology. aibio.space tracks 2,820 public biotech companies worldwide and publishes investor news on them. - **Company**: Kalaris Therapeutics, Inc. - **Ticker**: KLRS - **Listing**: NASDAQ - **Country or territory**: United States - **Business scope**: Biotechnology - **ISIN**: US4829291065 - **Last quote in directory**: 2026-10-21 - **Directory source**: [Listing page](https://www.tradingview.com/symbols/NASDAQ-KLRS/) Listing facts come from our company directory, researched on October 22, 2026. A listing record does not certify that a security currently trades. [Tell us about a change](https://aibio.space/reputation/#update). Work at this company? [Claim this page](https://aibio.space/claim/). Published and maintained by aibio.space. Not investment advice. [How we work](https://aibio.space/disclosures/). Who manages this page **This page is managed by aibio.space.** The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. [How we work](https://aibio.space/disclosures/#paid) · [Terms](https://aibio.space/terms/#news) · [Request a correction](https://aibio.space/reputation/#update) --- Source page: https://aibio.space/companies/kalaris-therapeutics/. Facts in aibio.space stories are checked against company filings and releases; opinion is labelled. Cite as: aibio.space, "Kalaris Therapeutics (KLRS) news: merger", 2026-10-31, https://aibio.space/companies/kalaris-therapeutics/